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Background: Although the whole tumor cell vaccine can provide the best source of immunizing antigens, there is
still a limitation that most tumors are not naturally immunogenic. Tumor cells genetically modified to secrete
immune activating cytokines have been proved to be more immunogenic. IL-18 could augment proliferation of
T cells and cytotoxicity of NK cells. GM-CSF could stimulate dendritic cells, macrophages and enhance presentation
of tumor antigens. In our study, we used mouse GM-CSF combined with IL-18 to modify Lewis lung cancer LL/2,
then investigated whether vaccination could suppress tumor growth and promote survival.
Methods: The Lewis lung cancer LL/2 was transfected with co-expressing mouse GM-CSF and IL-18 plasmid by cationic
liposome, then irradiated with a sublethal dose X ray (100 Gy) to prepare vaccines. Mice were subcutaneously immunized
with this inactivated vaccine and then inoculated with autologous LL/2 to estimate the antitumor efficacy.
Results: The studies reported here showed that LL/2 tumor cell vaccine modified by a co-expressing mouse GM-CSF
and IL-18 plasmid could significantly inhibit tumor growth and increased survival of the mice bearing LL/2 tumor
whether prophylactic or adoptive immunotherapy in vivo. A significant reduction of proliferation and increase of
apoptosis were also observed in the tumor treated with vaccine of co-expressing GM-CSF and IL-18. The potent
antitumor effect correlated with higher secretion levels of pro-inflammatory cytokines such as IL-18, GM-CSF,
interferon-γ in serum, the proliferation of CD4+ IFN-γ+, CD8+ IFN-γ+ T lymphocytes in spleen and the infiltration of
CD4+, CD8+ T in tumor. Furthermore, the mechanism of tumor-specific immune response was further proved by 51Cr
cytotoxicity assay in vitro and depletion of CD4, CD8, NK immune cell subsets in vivo. The results suggested that the
antitumor mechanism was mainly depended on CD4+, CD8+ T lymphocytes.
Conclusions: These results provide a new insight into therapeutic mechanisms of IL-18 plus GM-CSF modified tumor
cell vaccine and provide a potential clinical cancer immunotherapeutic agent for improved antitumor immunity.
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Lung cancer is the major cause of cancer-related mortality
in patients worldwide [1] in which non-small cell lung
cancer (NSCLC) accounts for 85%. Last few decades
immunotherapy has become an important part in oncol-
ogy treatment. Immunotherapy has a major advantage to
specifically target tumor cell relative to normal cell, thereby* Correspondence: denghongx@scu.edu.cn
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stated.minimizing nonspecific toxicities [2]. Cancer vaccines as
the best choice of immunotherapy are available for clinical
trials in recent years, ranging from single peptide and
recombinant viral vector vaccinations to whole cell
therapies [3-6]. However, evidence from preclinical models
suggests that the immune system often fails to reject
spontaneously arising tumors for the absence of suffi-
ciently immunogenic tumor specific antigens (TSA) [7].
In this case, the whole tumor cell represents the best
source of immunizing antigens without knowledge of
any specific antigen targets. Unfortunately, studies aimed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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that most tumors are not naturally immunogenic due to
immune-editing [8], a process that allows tumor to evolve
during continuous interactions with the host immune
system and eventually escape from immune surveil-
lance. Therefore, improving the immunogenic of tumor
cell became very important. In fact, researchers have
found that genetically modified tumor cell with se-
creted immune activating cytokines has the ability to
enhance the immunogenic and induce systemic antitu-
mor immune responses [9].
IL-18, IFN-γ-inducing factor, is secreted mainly by
activated macrophages and DCs [10]. It could induce the
proliferation and enhance the cytotoxicity of both T and
NK cells [11]. IL-18 has shown to have anti-tumor
effects in several murine tumor models when transferred
into tumor cells, alone [12-14] or in combination with
IL-12 [15] or IL-23 [16]. Similar with IL-12, IL-18 also
has the ability to inhibit tumor angiogenesis and growth
[17,18]. Moreover, combination of IL-12 and IL-18 can
play an important role in progression and metastasis of
gastric cancer [19].
GM-CSF is a potent cytokine activator of APCs and
plays an important part in breaking tolerance and the
development of antitumor immune responses [20]. There-
fore, GM-CSF was often evaluated as cancer vaccine ad-
jutants. GM-CSF genetically modified the irradiated
whole tumor cells (GVAX) is very effective when used
to trigger immune responses. In mouse models, prophy-
lactic vaccines using GM-CSF modified tumor cells can
engender protective immunity to delay tumor growth
[21]. Similarly, in cancer patients, GM-CSF secreting
allogeneic tumor vaccines have also been developed for
clinical testing and evaluated in pancreatic cancer, breast
cancer, and hormone-resistant prostate cancer [22-24].
More encouragingly, the FDA has approved a therapeutic
prostate cancer vaccine which modified by fusion protein
that combines recombinant prostate acid phosphatase
(PAP) with recombinant GM-CSF called Sipuleucel-T
in April 2010.
However, no previous studies, to our knowledge, have
examined the strategy that using combination of IL-18
and GM-CSF gene to modify tumor cell vaccine in a sin-
gle tumor model. In the present study, we utilized the
mouse IL-18 combined with GM-CSF to modify the
poorly immunogenic Lewis lung cancer LL/2 [25]. It is
critical for our study to establish the generality of an
immunostimulatory effect of a tumor vaccine product
modified with combined immune stimulating factors.
Compared with LL/2 blank or LL/2 irradiated vaccine
group, the results showed that vaccine co-expressing IL-18
and GM-CSF group markedly delayed tumor growth
and prolonged the overall survival either in prophylac-
tic or adoptive experiments in vivo. We also found thatthis vaccine induced greater infiltration of spleen cells
and higher production of IFN-γ in vitro. The antitumor
response is also tumor specificity by 51Cr CTL assay
in vitro and mainly dependenton CD4+, CD8+ T lympho-
cyte by depletion in vivo. The findings from our study
suggest that the combination of GM-CSF and IL-18
gene should be very promising for improving the im-
munogenic of tumor vaccine in a synergetic manner.
Methods
Ethics
Experimental research that is reported in the manuscript
have been performed with the approval of the Animal
Care and Welfare Committee of CIH-CAM S-PUMC
(approval date: 20 June 2009; approval number: 20120002).
All the experimental research on animals followed the
National Institutes of Health Guide for the Care and
Use of Laboratory Animals (publication no. 85–23,
revised 1985).
Mice
Female 5-week-old C57BL/6 mice (the laboratory Animal
Center of Sichuan University, Chengdu, China) were kept
under specific pathogen-free conditions in State Key
Laboratory of Biotherapy, West China Hospital, Sichuan
University.
Cell culture and transfection
Mouse Lewis lung cancer cell line LL/2 (ATCC), hybrid-
oma cell lines CD4 (PK136, ATCC), CD8 (Clone2.43,
ATCC) were cultured in DMEM medium with 10% FBS
(Gibco-BRL, Gaithersburg, MD. USA), NK (GK1.5, ATCC)
in IMEM medium with 20% FBS (Gibco-BRL, Gaithers-
burg, MD. USA). All mediums were supplemented with
20 mM L-glutamine, 100 U/ml of penicillin and 100 μg/ml
of streptomycin. All tumor cells were maintained at 37°C
in a humidified atmosphere containing 5% CO2. Cell
transfection was carried out using Cationic liposome
DOTAP-Chol according to the manufacturer’s standard
procedure [26].
Generation of pIRES-double MCS eukaryotic expression
vector
Eukaryotic expression vector pIRES-double MCS was
reformed with pIRES empty plasmid and pEGFP-N1
plasmid. First, multiple cloning sites (MCS) sequence
from pIRES empty plasmid was synthetized into pUC57
empty vector (GenScript Co, Ltd. Nanjing, China), and
NheI, NotI restriction enzyme cutting sites were intro-
duced into MCS sequence, we then cut pUC57 vector
and pEGFP-N1 plasmid with NheI, NotI restriction
Enzymes, respectively, restriction fragments were recycled
using Gel Extraction Kit and connected with T4 ligase.
The reconstructive vector was named pIRES-DMCS,
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prepared using the Qiagen Endo-free Giga kit (Qiagen,
Hilden, Germany).
Construction of co-expressing IL-18 and GM-CSF plasmid
To generate an eukaryotic co-expression IL-18 and GM-
CSF vector, an pIRES-DMCS vector with double cloning
sites has been reformed in our lab (State Key Laboratory
of Biotherapy, Chengdu, Sichuan, China). It is abbrevi-
ated as MCS. Mouse GM-CSF gene (GenBank:X03019.1)
was first cloned and inserted into MCS between the
restriction sites SacI and SacII, abbreviated as MCS-
mGM-CSF. To clone mIL-18 into MCS-mGM-CSF, the
newly constructed MCS-mGM-CSF vector was then
linearized with EcoRI and XbaI digestion. Mouse IL-18
(GenBank:NM_008360.1) was inserted into the linear-
ized vector and abbreviated as MCS-mGM-CSF + IL-18.
Meanwhile, we also inserted mIL-18 into MCS by the
restriction sites EcoRI and XbaIas control group, abbre-
viated as MCS-mIL-18. Plasmids were extracted using
Endo Free Plasmid Giga kits (Qiagen, Hilden, Germany)
from DH5α Escherichia coli transformants and stored
at −20°C before use. The concentration was determined by
measuring A260/A280 ratio using UV spectrophotometry.
Vaccine preparation
LL/2 tumor cells were respectively transfected with
MCS, MCS-mGM-CSF, MCS-mIL-18 and MCS-mGM-
CSF + IL-18 plasmids by Cationic liposome (DOTAP-
Chol: DNA = 6:1). For 48 hours, the tumor cells were
extensively digested and washed three times, then sus-
pended in 1 ml serum free DMEM medium. The cell
resuspension in each group was irradiated with a sub-
lethal dose X-ray (100 Gy) [27] by irradiator (RS-2000
biological irradiator, Rad Source Technologies, Inc.
Suwanee, GA). Irradiated tumor cells were used for fur-
ther study, including morphologic observation, prolifer-
ation assay, detection of cytokine levels and animal
experiments.
Cell proliferation assays
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay was used to determine the prolifer-
ation rate of the cells as described previously [28]. After
irradiation, cells were immediately plated in 96-well
plated. At time points of 0, 24, 48 and 72 h, the absorb-
ance was recorded using a 96-well spectrophotometer at
wavelength of 570 nm. For analysis of cell viability, values
from wells with no cells were subtracted for background
correction and the data determined as a percent of the
untreated control samples. Each assay was performed
in three replicates. Normal LL/2 tumor cell was used as
control group.Cytokine analysis
In vitro the supernatants of irradiated groups transfected
with plasmids as described previously were collected on
48 h, and the concentration of IL-18, GM-CSF were ana-
lyzed using ELISA kits (eBioscience Inc, San Diego, CA,
USA). Meanwhile the expression of IL-18, GM-CSF in
the supernatants of non-irradiated groups were also
detected. For in vivo cytokine analysis, mice were immu-
nized with various tumor cell vaccines subcutaneously.
Serum from each group including non-immunized group
was collected through caudal vein on 2 day, 4 day, 6 day
and 8 day after the third immunization respectively.
IL-18, GM-CSF and Th1/Th2 cytokines such as INF-γ,
TNF-α, TGF-β, IL-10 were analyzed by ELISA kits
(eBioscience Inc, San Diego, CA, USA).
Prophylactic immunotherapy in vivo
To assess the efficacy of LL/2 tumor cell vaccines
in vivo, C57BL/6 mice (5–6 weeks) were divided into
different vaccine groups and immunized subcutaneously
with irradiated vaccines (1 × 106 cells per mouse) on the
left at 1, 3, 4 week respectively [29,30]. Non-immunized
group as control was injected with serum free medium
alone. All mice were then subcutaneously challenged
with 1 × 106 LL/2 cells on the right after 7 days at the
third immunization. About one week, tumor volume
could be measured every three days and each mouse was
taken for measurements. We measured for six times in
Prophylactic immunotherapy. Tumor volume was calcu-
lated using the formula volume = length × width2/2. The
survival curve could also be surveyed.
Adoptive immunotherapy in vivo
As the method described in prophylactic immunother-
apy, splenic lymphocytes of all groups were isolated by
lymphocyte separation fluid (Tianjin Chuanye biochem-
ical products company, Tianjin, China) according to
the manufacturer’s standard procedure after the third
immunization. Splenic lymphocytes were then counted
and injected i.v (1 × 107 cells per mouse) into mice
which were inoculated LL/2 tumor cells (1 × 106 cells
per mouse) subcutaneously 3 days ago. Adoptive im-
munotherapy of splenic lymphocytes was repeated every
2 days for 5 times. About one week, tumors could be
measured every 3 days and calculated using the formula
volume = length × width2/2. We measured for six times
in adoptive immunotherapy. The survival curve could
also be surveyed.
51Cr cytotoxic assay in vitro
The cytolytic activity of tumor-specific CTL was evalu-
ated by 51Cr-releaseassay. As described in prophylactic
immunotherapy, spleen cells from the immunized mice
and control group (non-immunized mice) were prepared
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cells. Splenocytes as effector cells were then co-cultured
with 51Cr-labeled LL/2 cells as target cells at 80:1, 40:1,
20:1, 10:1 E:T ratios for 4 h under 37°C, 5% CO2. There-
after, the supernatant was obtained and 51Cr release was
assessed. The percentage of specific lysis was calculated
by the following formula: (c.p.m.experiment release-c.p.
m.spontaneous release)/(c.p.m.maximum release-c.p.m.
spontaneous release) × 100. Spontaneous release was de-
termined by incubation of the labeled target cells with-
out effector cells. For maximum release, labeled target
cells were treated with detergent.
Depletion of immune cell subsets in vivo
Immune cell subsets could be depleted as described pre-
viously [31,32]. As described in prophylactic immuno-
therapy, mice immunized were injected intraperitoneally
with 500 μg anti-CD4 (GK1.5), anti-CD8 (clone2.43),
anti-NK (PK136) monoclonal antibody (mAb) produced
in hybridoma cell and isotype control rat IgG at 1 day
before every immunization and three days later for 6
times, respectively. Mice were then challenged with LL/2
tumor cell after 7 days at the last depletion. Tumor
growth in different subsets was estimated. The depletion
of CD4, CD8 T lymphocytes and NK cells was consistently
greater than 98% determined by flow cytometry [31].
Flow cytometry and antibodies
The following anti-mouse monoclonal antibodies (mAbs)
were used for flow cytometry: anti-CD4-PE, anti-CD8-PE,
anti-IFN-γ-FITC (BD Bioscience, USA). Flow cytometry
was performed using a flow cytometer (Epics X L; Beckman
Coulter Inc., Brea, CA, USA) equipped with Expo32 soft-
ware (Beckman Coulter) under the standard procedure.
T lymphocyte infiltration in tumor tissue
After the last measurement of tumor volume in prophy-
lactic immunotherapy, tumors were resected and frozen
sections were used for analysis of T lymphocyte infiltra-
tionby immunofluorescence. The following anti-mouse
primary antibodies (mAbs) were used rat anti-mouse
CD8, rat anti-mouse CD4, rat anti-mouse NK and the
second antibodies were goat anti-rat IgG-TR and goat
anti-rat IgG-FITC (Abcam, USA), respectively.
Immunohistochemistry
Thirty days after the last measurement of tumor volume
in prophylactic immunotherapy, mice were sacrificed and
paraffin-embedded tumor tissue sections were used for
the examination of PCNA, activated-caspase-3 (Abcam,
Cambridge, UK) and tunnel (Promega, Madison, WI).
Sections were scored under light microscopy (X200) by
three independent pathologists, who analyzed three dif-
ferent fields per section.Statistical analysis
Statistical significance of difference between the two
groups was determined by the Student paired-test. The
Kaplan-Meier plot for survival was assessed for significance
using the log-rank test (SPSS software; version 16.0; SPSS
Inc, Chicago, IL, USA). P < 0.05 was considered significant.Results
Preparation of irradiated LL/2 tumor cell vaccine
co-expression IL-18 and GM-CSF
Three eukaryotic expression plasmids expressing IL-18
alone, GM-CSF alone, or IL-18 and GM-CSF were
generated as described in Methods (see workflow in
Additional file 1: Figure S1). LL/2 tumor cells were then
transfected with MCS-GM-CSF, MCS-IL-18, MSC-GM-
CSF + IL-18 and the empty MCS, respectively. Forty-
eight hours later, the cells were harvested, and irradiated
under a sublethal dose X-ray (100 Gy). The efficiency of
transfection was detected by GFP plasmid transfected
into LL/2 using DOTAP-Chol (Figure 1A). In order to
assess the feasibility of the irradiated vaccine, we culture
the irradiated cells, and evaluated the cell state of adher-
ence and proliferation using morphological observation
and MTT at 24 h, 48 h and 72 h. The data showed that
irradiated cells could be adherence but not proliferation
(Figure 1B) compared with normal tumor cell. The
results indicated that irradiated cells could not prolifer-
ate in vitro. Moreover, the irradiated cells were further
proved to have no tumorigenicity in prophylactic im-
munotherapy when injected subcutaneously. Meanwhile,
the irradiated cells still kept cell viability, so they pos-
sessed the ability to secrete local cytokines continuously
after injecting subcutaneously. Therefore, the tumor cell
vaccines satisfied the optimized condition “no tumori-
genicity but secreting cytokines”.
To further investigate whether IL-18 and GM-CSF
expression could be affected by irradiation. Culture su-
pernatants were also obtained 48 h after irradiation and
determined by ELISA. Secretion of cytokines was re-
duced a little after irradiation, but there was no signifi-
cantly statistical difference (Figure 1C). The expression of
GM-CSF from MCS-GM-CSF and MCS-GM-CSF + IL-18
vaccines were 1327 ± 178 pg/ml (p = 0.111), 1314 ± 147 pg/
ml (p = 0.115) compared with before irradiation, respect-
ively. IL-18 from MCS-IL-18 and MCS-GM-CSF + IL-18
vaccines were 1468 ± 100 pg/ml (p = 0.457), 1401 ± 94 pg/
ml (p = 0.191), respectively. Meanwhile mRNA was also
extracted and analyzed by RT-PCR. We found that the
expression level of mRNA had no markedly change be-
tween irradiation and non-irradiation cells (see results in
Additional file 1: Figure S2). These results indicated that
irradiation had no significantly influences on the expres-
sion of IL-18 and GM-CSF.
Figure 1 Characterization of LL/2 cell vaccine co-expression IL-18 and GM-CSF. (A) The GFP fluorescent images represents transfection
efficiency of LL/2 transfected with freeze-drying cationic liposome-GFP. (B) Cell morphology was imaged at 24 h and 72 h before or after irradiation,
respectively (original magnification, ×200). The proliferation of LL/2 cell was measured by MTT at 24 h, 48 h and 72 h before or after irradiation, respectively
(P < 0.01). (C) The secretion of IL-18 and GM-CSF in cell supernatant was detected by ELISA between before irradiation and after irradiation (P > 0.05),
respectively. Columns represents mean; bars represents SD.
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co-expression IL-18 and GM-CSF in prophylactic
immunotherapy in vivo
To ascertain whether tumor cell vaccine co-expression
IL-18 and GM-CSF induced tumor growth inhibition in
syngeneic mice, we formulated an schedule (Figure 2A),
and strictly immunized mice, inoculated LL/2 tumor cells,
measured tumor volume and dissected as previously de-
scribed in methods of prophylactic immunotherapy. MCS-
GM-CSF + IL-18, MCS-IL-18 and MCS-GM-CSF vaccines
showed an average tumor volume of 180.6 ± 34.2 mm3
(p < 0.01), 818.6 ± 87.9 mm3 (p = 0.042) and 785.3 ±
91.8 mm3 (p = 0.041), respectively, showing 84.8% (MCS-
GM-CSF + IL-18), 31.3% (MCS-IL-18) and 34.1% (MCS-
GM-CSF) tumor growth inhibition compared with LL/2
control group (1191.7 ± 173.7 mm3) (Figure 2B). Further-
more, MCS-GM-CSF + IL-18-treated mice showed higher
survival rates compared with either MCS-GM-CSF or
MCS-IL-18 (P < 0.01). All animals treated with MCS-GM-
CSF + IL-18 vaccine remained alive 65 days after the be-
ginning of inoculation, whereas only 40% of those treated
with MCS-GM-CSF and 0% of those treated with MCS-
IL-18 survived for the same period of time (Figure 2C).
Mice in LL/2 control group all died at 45 days after the
beginning of inoculation. The tumor weight in MCS-GM-
CSF + IL-18 vaccine group also showed a significant differ-
ence compared with either MCS-GM-CSF (p = 0.034) or
MCS-IL-18 (p = 0.017) (Figure 2D). Taken together, theseresults suggest that MCS-GM-CSF + IL-18 vaccine signifi-
cantly enhanced antitumor efficacy and prolonged survival
compared with either MCS-GM-CSF, MCS-IL-18 or LL/2
control group in the LL/2 mouse Lewis lung cancer model.Tumor-specific antitumor effect in adoptive
immunotherapy in vivo
To determine whether prophylactic immunotherapy pro-
duced tumor-specific antitumor effect in vivo, C57BL/6
mice were immunized as described in prophylactic
immunotherapy and splenocytes were isolated 3 days
following the last immunization. We then conducted
adoptive immunotherapy under the planed scheme
(Figure 3A). As expected, adoptive immunotherapy also
achieved striking tumor-specific antitumor effect. MCS-
GM-CSF + IL-18, MCS-IL-18 and MCS-GM-CSF vaccines
showed an average tumor volume of 622.4 ± 472.9 mm3
(p < 0.01), 1617.8 ± 308.7 mm3 (p = 0.017) and 1614.1 ±
512.7 mm3 (p = 0.011), respectively, showing 80.3%
(MCS-GM-CSF + IL-18), 48.7% (MCS-IL-18) and 48.8%
(MCS-GM-CSF) tumor growth inhibition compared with
LL/2 control group (3153.7 ± 411.1 mm3) (Figure 3B).
MCS-GM-CSF + IL-18 group also showed significant
difference compared with MCS-IL-18 (p = 0.032) and MCS-
GM-CSF (p = 0.049). The survival rate of MCS-GM-CSF +
IL-18 group was markedly prolonged when compared with
either MCS-GM-CSF, MCS-IL-18 or control group (p < 0.01)
Figure 2 Prophylactic immunotherapy induced potent antitumor effects and prolonged survival rate of LL/2 tumor-bearing mice.
(A) The schedule of prophylactic immunotherapy. The detailed process as described in prophylactic immunotherapy Methods. Groups divided
into LL/2 control and LL/2, MCS, MCS-GM-CSF, MCS-IL-18, MCS-GM-CSF + IL-18 vaccines. (B) Tumor volume of mice immunized with vaccine
co-expression IL-18 and GM-CSF decreased significantly compared with other groups (p < 0.01, n = 7). (C) Kaplan-Meier survival analysis showed that
mice treated with vaccine co-expression IL-18 and GM-CSF had longer survival than other groups (p < 0.01, n = 7). (D) Tumor weight in combined
vaccine group was smaller than other groups (p < 0.01, n = 7). Error bars represent SD.
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munotherapy induced tumor-specific antitumor effect.
Co-expression IL-18 and GM-CSF vaccine increased
expression of IL-18, GM-CSF and IFN-γ in vivo
To determine the amount of IL-18 and GM-CSF produced
in experimental group, serum samples were harvested at
2, 4, 6, and 8 days following the last immunization through
tail vein respectively. Mice immunized with MCS-IL-18 or
MCS-GM-CSF + IL-18 showed peak concentrations of
IL-18 at 6 day (157.1 ± 20.1 pg/ml for MCS-IL-18 and
156.09 ± 27.3 pg/ml for MCS-GM-CSF + IL-18) and
reached significant differences (p = 0.003 for MCS-IL-18
and p = 0.004 for MCS-GM-CSF + IL-18) compared with
control group (Figure 4A). Similarly, MCS-GM-CSF or
MCS-GM-CSF + IL-18 produced significantly higher
levels of GM-CSF at 6 day (167.3 ± 6.3 pg/ml for MCS-
GM-CSF and 151.1 ± 8.1 pg/ml for MCS-GM-CSF + IL-
18) and reached significant differences (p = 0.002 for
MCS-GM-CSF and p = 0.005 for MCS-GM-CSF + IL-
18) compared with control (Figure 4B). Given thebiological effects of IL-18 and GM-CSF, we examined
several Th1 or Th2 cytokine levels, including INF-γ,
TGF-β, TNF-α and IL-10. In comparison, high levels of
INF-γ (176.7 ± 58.6 pg/ml, p = 0.001) was showed in
MCS-GM-CSF + IL-18-treated mice compared with con-
trol group at 6 day (Figure 4C). Interestingly, TNF-α was
elevated 6 day in control groups (Figure 4E), IL-10 was
also reached at peak 6 day in MCS-GM-CSF + IL-18 group
(Figure 4F). Th2 cytokines, TGF-β (Figure 4D) showed ir-
regular expression but no significant difference between
MCS-GM-CSF + IL-18 and control groups (p > 0.05). These
data suggested co-expression IL-18 and GM-CSF vaccine
produced significantly higher amounts of IL-18, GM-CSF
and INF-γ than other groups, enhancing Th1 cytokine and
suppressing Th2 cytokine in the tumor microenvironment.
Co-expression IL-18 and GM-CSF vaccine increased the
frequencies of CD4+INF-γ+ T, CD8+INF-γ+ T in spleen and
infiltration of CD4+T, CD8+T in tumors
To further explore possible mechanism of antitumor ac-
tivity in mice immunized with MCS-GM-CSF + IL-18
Figure 3 Adoptive immunotherapy produced a tumor-specific immune response and prolonged survival rate of LL/2 tumor-bearing
mice. Splenic lymphocytes of all groups were isolated after the third immunization and injected i.v (1 × 107cells per mouse) into mice which
were inoculated LL/2 tumor cells (1 × 106 cells per mouse) subcutaneously 3 days ago. Adoptive immunotherapy of splenic lymphocytes was
repeated every 2 days for 5 times. (A) The schedule of prophylactic immunotherapy. (B) Tumor volume of mice adopted with lymphocytes from
co-expression IL-18 and GM-CSF group co-expression IL-18 and GM-CSF group effectively inhibited compared with other groups (p < 0.01, n = 7).
(C) Kaplan-Meier survival analysis showed that the survival of co-expression IL-18 and GM-CSF group was significantly prolonged (p < 0.01, n = 7). Error
bars represent SD.
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CD4+IFN-γ+ and CD8+IFN-γ+ double staining. As ex-
pected, there was a significant increase in the percentage of
CD4+IFN-γ+ (0.36%), CD8+IFN-γ+ (0.32%), CD4+ (28.06%)
and CD8+ (16.32%) T lymphocytes compared with LL/2
control group (0.02%, 0.02%, 2.87%, 2.62%, respectively.
p < 0.01) (Figure 5A). To obtain more insight into the
molecular mechanisms of cytokine-mediated inhibition
of tumor growth, we performed immunohistological
analysis. Frozen section studies analyzed the tumor-
infiltrating immune cells such as CD4+T, CD8+T and
NK within tumor microenvironment. Histological evalu-
ation of tumor sections revealed that large areas of tumors
treated with MCS-GM-CSF + IL-18 vaccine were necrotic.
In particular, tumors treated with MCS-GM-CSF + IL-18
vaccine were extensively infiltrated with higher numbers
of CD4+T, CD8+T immune cells compared with LL/2
control (p < 0.01), whereas tumors showed sparse NK
infiltration (p > 0.05) (Figure 5B). Moreover, denser im-
mune cell infiltration was observed not only around,
but also inside the remaining tumor tissues treated with
MCS-GM-CSF + IL-18 vaccine. These findings suggested
that co-expression IL-18 and GM-CSF vaccine enhanced
proliferation of CD4+INF-γ+ T, CD8+INF-γ+ T and in-
filtration of CD4+T, CD8+T cells.Co-expression IL-18 and GM-CSF vaccine effectively
inhibited proliferation and promoted apoptosis in vivo
Tumors were collected for analysis of proliferation and
apoptosis after the last tumor volume measurement.
Tumor cell proliferation was evaluated by using PCNA
staining. The expression of PCNA was dramatically reduced
in the co-expression IL-18 and GM-CSF vaccine-treated
group compared with other groups (Figure 6A, P < 0.05,
n = 7). Cleaved caspase-3 and TUNEL assay immunostain-
ing were carried out to detect apoptosis within the tumors.
Apoptosis cells were widely distributed in co-expression
IL-18 and GM-CSF vaccine-treated tumor tissue versus
control groups (Figure 6B and C, P < 0.05, n = 7). More-
over, an apparent increase in the number of apoptotic cells
was observed within the tumors from MCS-IL-18 vaccine-
treated group. The results showed that co-expression
IL-18 and GM-CSF vaccine-treated was clearly more po-
tent in suppressing proliferation and inducing tumor cell
apoptosis relative to mono-immunotherapy groups.
Generation of a tumor-specific immune response by 51Cr
in vitro and function of immune cell subsets in antitumor
activity in vivo
To further delineate the tumor-specific immune response
in vitro, a 51Cr-release assay was carried out. Splenocytes
Figure 4 Vaccine co-expression IL-18 and GM-CSF treatment increased local expression of IL-18, GM-CSF, and IFN-γ in vivo. Serum from
each group including non-immunized group was collected through caudal vein on 2 day, 4 day, 6 day and 8 day after the third immunization
respectively. ELISA was carried out to detect the level of IL-18 (A), GM-CSF (B), IFN-γ (C), TGF-β (D),TNF-α (E) and IL-10 (F) in serum respectively.
Experiments were performed in triplicate and repeated three times. Each data point indicates means ± SD. Vaccine co-expression IL-18 and
GM-CSF produced a synergistically higher levels of IL-18, GM-CSF and IFN-γ than LL/2 control group (P < 0.01, n = 7). TGF-β showed no
difference in all groups (P > 0.05, n = 7).
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the most potent LL/2-specific lytic activity on 4 hours after
exposure. The ratio of effector cells: target cells were 10:1,
20:1, 40:1 and 80:1. A significant CTL killing of splenocytes
from mice treated with MCS-GM-CSF + IL-18 or MCS-
IL-18 was 51.3 ± 2.2 and 42.5 ± 3.1 compared with LL/2
control (15.6 ± 1.0), respectively, at an effector-to-target
(E: T) ratio of 80:1 (Figure 7A, P < 0.01). To explore the
roles of immune cell subsets in antitumor activity elicited
by MCS-GM-CSF + IL-18 vaccine, we depleted CD4 or
CD8 T lymphocytes or NK cells through injection of the
corresponding blocking antibodies. Mice treated with mAb
against CD4 (Figure 7B) or CD8 T (Figure 7C) cells failed
to abrogate the antitumor activity (P > 0.05). In contrast,
depleted of NK (Figure 7D) or injected with isotype control
rat IgG (Figure 7E) still showed strongly antitumor activitycompared with control group (p < 0.01). These results fur-
ther illustrated the mechanism of antitumor activity mainly
depend on CD4+and CD8+T lymphocytes, not NK im-
mune cells.
Discussion
Numerous lines of evidence indicate that most tumors
can escape immune detection or elimination [33]. This
phenomenon is mainly caused by activation of immuno-
suppressive cells as well as down-regulation of effective
antigens and MHC expression which could dampen the
vigor of immune responses or induce apoptosis of
immune effector cells [34]. Some of these reasons can be
reversed by cytokines.
Recently, studies in mouse tumor models and in patients
have shown the importance of cytokine combinations in
Figure 5 Increased proliferation of CD4+INF-γ+ T, CD8+ INF-γ+ T in spleen and infiltration of CD4+T, CD8+T in tumors. Spleen lymphocytes
were isolated and stained for CD4, CD8 and INF-γ double staining antibodies by flow cytometry; Tumor tissue was obtained 3 days after the
last measurement of tumor volume, frozen sections were used for analysis of CD4, CD8 T and NK cell infiltration. (A) The proportion of CD4+INF-γ+ T,
CD8+ INF-γ+ T in co-expression IL-18 and GM-CSF-treated mice was significantly higher than control groups (P < 0.01, n = 7). Experiments were
performed in triplicate and repeated three times. (B) Immunofluorescence staining of tumor tissue with CD4, CD8 and NK antibody showed
that CD4+, CD8+ T cell infiltrations was significant enhanced in co-expression IL-18 and GM-CSF-treated group as compared with control
groups (P < 0.01, n = 7) (original magnification, ×200).
Tian et al. BMC Cancer 2013, 14:48 Page 9 of 13
http://www.biomedcentral.com/1471-2407/14/48
Figure 6 Effects of co-expression IL-18 and GM-CSF vaccine on cell apoptosis and proliferation in vivo. (A) Tumor tissues were stained with
PCNA. The number of cancer cell nuclei that were strongly PCNA positive was counted as a ratio of immunoreactive-positive cells to the total number of
cells counted (original magnification, ×200, * P < 0.05, **P < 0.01). (B) Tumor tissues were stained with caspase-3. Caspase3-labeling index was estimated
as the percentage of neoplastic cells with positive nuclear staining of the total number of neoplastic cells counted (original magnification, ×200, *P < 0.05,
**P < 0.01). (C) Induction of apoptosis was indicated by TUNEL assay. The TUNEL-positive cells display dark green nuclei and are observed under a
fluorescence microscope, and the percentage of apoptotic cells was determined as described in the Methods (original magnification, ×200, *P < 0.05,
**P < 0.01). Columns, mean; bars, s.d.
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ample, a clear synergy between interleukin-2 (IL-2) and
IL-12 was first described in a poorly immunogenic tumor
(MCA205) after i.t. administration using adenoviral vec-
tors [35]. The combination of IL-12 and IL-18 used to
modify autologous tumor cell vaccine by means of the
EBV/Lipoplex or oncolytic adenovirus could synergistically
induce significant antitumor effects [15,29]. These results
showed a prospect of combining two potentially synergistic
cytokines to modify tumor cell vaccine, thereby improving
the immunogenicity and tumor-specific immunity.
In our current study, we choose the IL-18 and GM-
CSF to genetically modify the Lewis lung cancer cell.
IL-18 induces the proliferation and enhances the cyto-
toxicity of both T and NK cells [11]. GM-CSF may play an
important role in the maturation or function of antigen
presenting cells. In multiple murine models, Vaccination
with irradiated tumor cells engineered to secrete GM-CSF
involves enhanced tumor antigen presentation by re-
cruited dendritic cells (DCs) and macrophages [36]. After
irradiation with a sublethal dose X-ray (100 Gy), we have
succeeded in generating an effective LL/2 tumor cell
vaccine co-expressing mouse IL-18 and GM-CSF. Thevaccine has the ability to secreting cytokines, but has
no tumorigenicity (Figure 1B-C). In animal study, we
found the vaccine could significantly inhibit the tumor
growth and prolong the survival both in prophylactic
immunotherapy (Figure 2A-D) and in adoptive im-
munotherapy (Figure 3A-C). The antitumor immunity
is specific response proved in adoptive immunotherapy.
Due to the pleiotropy of vaccine, the possible mechanism is
that localized expression of GM-CSF by tumor cell vaccine
co-expression GM-CSF and IL-18 might specifically recruit
dendritic cells (DCs) or macrophages and enhance whole
tumor-antigen presentation, IL-18 secreted by vaccine
could further promote the proliferation and cytotoxicity
of T or NK cells which received tumor antigens pre-
sented by activated host antigen presenting cells.
To show the mechanism underlying the enhanced an-
titumor effect mediated by vaccine co-expression IL-18
and GM-CSF, we next detected the expression of Th1
or Th2 cytokine in serum. Our data showed that Th1
cytokines, including IL-18, GM-CSF and INF-γ, were
markedly elevated in vaccine co-expression IL-18 and
GM-CSF-treated mice (Figure 4A-C). The results indi-
cated that vaccine co-expression IL-18 and GM-CSF
Figure 7 CTL-mediated tumor-specific cytotoxicity in vitro and abrogation by the depletion of immune cell subsets in vivo. (A) 51Cr-release
assay. LL/2 cells were labeled with 51Cr and incubated with activated T cells isolated from mice immunized with vaccines or naive mice at 80:1, 40:1,
20:1 and 10:1 T: E ratios for 4 hours. Spleen T lymphocytes derived from mice treated with vaccine co-expression IL-18 and GM-CSF showed higher
cytotoxicity against parental LL/2 cells than those from the other groups. Each data point indicates means ± SD. Experiments were performed
in triplicate and repeated three times. **P < 0.01. (B-F) Antitumor immunity was abrogated by anti-CD4 (GK1.5), anti-CD8 (clone2.43), anti-NK
(PK136) monoclonal antibody (mAb) produced in hybridoma cell and isotype control rat IgG for 6 times, respectively. Tumor volume was measured.
Depletion of CD4 T lymphocytes (C) and CD8 T lymphocytes (D) showed complete abrogation of the antitumor activity of vaccine co-expression IL-18
and GM-CSF (P > 0.05, n = 7). In contrast, treatment with anti-NK (E) or isotype rat IgG (F) had no effect (P < 0.01, n = 7). Each data point indicates
means ± SD.
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could secrete pro-infammatory cytokine. Interestingly,
we found that tumor necrosis factor (TNF-α) showed
higher expression level at 6 day in control groups
(Figure 4E). The inflammatory cytokine TNF-α could
bind to its receptors and induce a signaling cascade
that induces transcriptional regulation of mediators
which are key to cell survival, invasion, angiogenesis,
and impairment of immune surveillance in tumor biol-
ogy [37,38]. The reason why TNF-α was elevated in
control group may be that its tumor-promoting role
which has been recently demonstrated in mouse cancer
models [39,40]. In these models and in human cancers,
TNF-α is produced by malignant or host cells within
the tumor microenvironment. The mechanisms of ac-
tion of TNF-α in the tumor microenvironment could
be via induction of a pro-angiogenic phenotype inrecruited monocytes [41], impairment of immune sur-
veillance through T cell suppression [42]. Moreover, we
also found immunosuppressive factor IL-10 was ele-
vated and reached a peak on the day 6 in combined
vaccine group (Figure 4F). Previous study has suggested
that IL-10 contributes to an immune suppressive tumor
microenvironment. It can inhibit the expression of
MHC molecules and co-stimulatory molecules at sev-
eral levels [43]. It has also been demonstrated that IL-
10 can impair secondary CD8+T cell responses [44],
whereas viral and tumor clearance can be enhanced in
the absence of IL-10 [45,46]. Recent study proved that
IL-10 is required for efficient immune surveillance
against the incidence and progression of endogenously
arising skin tumors. It induces the expression of MHCI
and the production of cytotoxic enzymes, IFN-γ in
tumor-infiltrating CD8+T cells in tumors [47]. These
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IL-10 was induced in combined vaccine group. TGF-β
was no obvious difference in all groups (Figure 4D). In
agreement with previous findings, We also found the
proportion of CD4+INF-γ+ T, CD8+ INF-γ+ T in spleen
was also higher in vaccine co-expression IL-18 and
GM-CSF treated than other groups (Figure 5A).
Tumor microenvironment has been shown to establish
immune-suppressive cytokine networks that favor the
suppression of an antitumor immune response and
eventually generate tumor proliferation, angiogenesis
and metastasis. Therefore, it is critical for activated
tumor-specific T effector cell and NK cell to infiltrate
and generate antitumor immunity effectively within the
tumor microenvironment. Immunohistochemical results
showed immense necrotic regions as well as infiltration of
CD4+T and CD8+T cells into the tumor tissues of vaccine
co-expression IL-18 and GM-CSF treated mice compared
with other groups, however, infiltration of NK was not
obvious in all groups (Figure 5B). To our knowledge for
the first time, low dosing of IL-18 could mediate im-
munosuppression on the NK cell arm of immunity. Im-
portantly, IL-18 could drive the expression of PD-1 on
mature NK cells, whereas PD-1 receptors were often
highly expressed on tumors [48]. It may induce apop-
tosis and no infiltration of NK cells. Certainly, further
studies will be needed to clarify this question. To fur-
ther prove specificity of antitumor immunity and analyze
tumor-specific immune cells, we showed that mice immu-
nized with vaccine co-expression IL-18 and GM-CSF had
enhanced CTL activity at 80:1 compared with control
group (Figure 7A). Depletion of CD4 or CD8 T lym-
phocytes were not protected from tumor challenge, in
contrast, depletion of NK still possessed strong anti-tumor
activity compared with control group (Figure 7B-F). These
results further support the question of infiltration of im-
mune cells in tumor and were accordance with previous
results.
Conclusions
Taken together, we showed that vaccination with irradi-
ated, autologous Lewis lung cancer cell LL/2 engi-
neered by combination of IL-18 and GM-CSF improved
the immunogenicity. Immunization with this vaccine
induced an antitumor immune response, especially of
tumor-specific CTLs, and prolonged the overall sur-
vival of tumor-bearing mice. Our data also demon-
strates that the finding provides a novel underlying
mechanism of combination therapies via IL-18 and
GM-CSF that promoted tumor antigen presentation
and induced proliferation of tumor-specific T cells.
These results also provide a potential clinical cancer
immunotherapeutic agent for the generation of im-
proved antitumor immunity.Additional file
Additional file 1: Figure S1. Construction of pIRES-double MCS vector
and Verification of pIRES-mGM-CSF + IL-18 plasmid. In order to reform an
eukaryotic expression vector with characteristics of double cloning sites,
easy transfection and resistance selection. We synthetized multiple cloning
sites (MCS) sequence from pIRES empty plasmid and introduced NheI, NotI
restriction enzyme cutting sites into MCS sequence. Then pEGFP-N1 plasmid
and MCS sequencewere cut with NheI, NotI enzymes, respectively. (A)
The pIRES-double MCS vector was then constructed through molecular
experiments. Mouse IL-18 and GM-CSF were then cloned into pIRES-DMCS
using EcoRI, XbaI and SacI, SacII restriction Enzymes, respectively. (B) The
pIRES-mGM-CSF, pIRES-mIL-18 and pIRES-mGM-CSF + IL-18 plasmids were
validated. The results were showed in DNA electrophoresis. Figure S2.
The mRNA expression of IL-18 and GM-CSF between irradiation and
non-irradiation cells.
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